Francesca Carlino
Overview
Explore the profile of Francesca Carlino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parola S, Oing C, Rescigno P, Feliciano S, Carlino F, Pompella L, et al.
Front Genet
. 2024 Dec;
15:1480417.
PMID: 39678373
Testicular germ cell tumors (TGCTs), the most common malignancies affecting young men, are characterized by high sensitivity to cisplatin-based chemotherapy, which leads to high cure rates even in metastatic disease....
2.
Grisolia P, Tufano R, Iannarone C, De Falco A, Carlino F, Graziano C, et al.
J Transl Med
. 2024 Oct;
22(1):938.
PMID: 39407254
Background: Recent studies have highlighted the importance of the cell-free DNA (cfDNA) methylation profile in detecting breast cancer (BC) and its different subtypes. We investigated whether plasma cfDNA methylation, using...
3.
Carlino F, Feliciano S
Recenti Prog Med
. 2024 Jun;
115(6):26e-30e.
PMID: 38853739
Triple-negative breast cancers patients who relapse within 12 months from the end of neoaadjuvant chemotherapy represent a subgroup with a particularly poor prognosis, due to resistance to common chemotherapy treatments....
4.
Carlino F, Solinas C, Orditura M, Bisceglia M, Pellegrino B, Diana A
Front Oncol
. 2024 Mar;
14:1321654.
PMID: 38469228
No abstract available.
5.
Iovino F, Diana A, Carlino F, Ferraraccio F, Antoniol G, Fisone F, et al.
J Clin Med
. 2022 Dec;
11(23).
PMID: 36498560
Introduction: The mesenchymal-epithelial transition factor (c-MET) receptor is overexpressed in about 14−54% of invasive breast cancers, but its prognostic value in clinical practice is still unclear. Methods: In order to...
6.
Carlino F, Diana A, Ventriglia A, Piccolo A, Mocerino C, Riccardi F, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291765
Background: Approximately 45-50% of breast cancers (BCs) have a HER2 immunohistochemical score of 1+ or 2+ with negative in situ hybridization, defining the "HER2-low BC" subtype. No anti-HER2 agents are...
7.
Carlino F, Diana A, Piccolo A, Ventriglia A, Bruno V, De Santo I, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565233
Triple-negative breast cancer (TNBC) has been considered for many years an orphan disease in terms of therapeutic options, with conventional chemotherapy (CT) still representing the mainstay of treatment in the...
8.
Diana A, Carlino F, Buono G, Antoniol G, Famiglietti V, De Angelis C, et al.
Front Oncol
. 2022 Apr;
12:813462.
PMID: 35419293
Introduction: In luminal-like early breast cancer (BC), the lack of Progesterone Receptor (PR) expression generally correlates with more aggressive behavior but the clinical validity of low PR levels remains a...
9.
Diana A, Carlino F, Giunta E, Franzese E, Guerrera L, Lauro V, et al.
Curr Treat Options Oncol
. 2021 Apr;
22(5):45.
PMID: 33864145
About 70-80% of early breast cancer (BC) patients receive adjuvant endocrine therapy (ET) for at least 5 years. ET includes in the majority of cases the use of aromatase inhibitors,...
10.
Diana A, Carlino F, Franzese E, Oikonomidou O, Criscitiello C, De Vita F, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32235297
Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy...